Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted inhaled medicines for severe respiratory conditions. The company's pipeline is primarily focused on treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Its lead product candidates, AP01 and AP02, are inhaled formulations of the established anti-fibrotic small-molecule drugs pirfenidone and nintedanib. These therapies are designed to improve efficacy and reduce systemic side effects by delivering medication directly to the lungs. Additionally, Avalyn is advancing AP03, a fixed-dose combination of both drugs. Operating from its headquarters in Boston, the company aims to establish a new standard of care for patients with rare lung diseases.
No data found.